Neurogene Inc. (NGNE)
| Market Cap | 428.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -90.35M |
| Shares Out | 15.62M |
| EPS (ttm) | -4.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 106,721 |
| Open | 27.41 |
| Previous Close | 27.05 |
| Day's Range | 27.22 - 28.58 |
| 52-Week Range | 11.77 - 37.27 |
| Beta | 1.89 |
| Analysts | Strong Buy |
| Price Target | 63.57 (+131.59%) |
| Earnings Date | May 8, 2026 |
About NGNE
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The comp... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for NGNE stock is "Strong Buy." The 12-month stock price target is $63.57, which is an increase of 131.59% from the latest price.
News
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Transcript: Stifel 2026 Virtual CNS Forum
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Transcript: Leerink Global Healthcare Conference 2026
NGN-401 is advancing in a pivotal trial for Rett syndrome, with durable, multi-domain functional gains observed and a 12-month endpoint required for approval. Commercial launch will leverage in-house manufacturing and a network of US centers, with Europe as a future opportunity.
Neurogene Transcript: TD Cowen 46th Annual Health Care Conference
NGN-401 gene therapy for Rett syndrome is advancing through a phase III trial, with Breakthrough Therapy designation and strong early data showing multi-domain developmental gains and no plateau at 12 months. The EXACT platform enables regulated gene expression, and safety protocols are robust. Enrollment is on track, with a midyear data update expected.
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
NGN-401, a gene therapy for Rett syndrome, is progressing through a pivotal study with enrollment and dosing set to complete in Q2 2026. Early data show durable, multi-domain improvements, and the company is preparing for US commercialization while planning for European expansion.
Neurogene to Participate in Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Transcript: 44th Annual J.P. Morgan Healthcare Conference
NGN-401, a gene therapy for Rett syndrome, is progressing rapidly through the Embolden registrational trial, with strong interim data showing durable, multi-domain improvements. Commercial readiness and market access strategies are advancing, targeting a multi-billion-dollar opportunity.
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Transcript: Stifel 2025 Healthcare Conference
Interim data for NGN-401 in Rett syndrome show durable, multi-domain skill gains and a favorable safety profile, with six of eight patients meeting responder criteria. Enrollment for the pivotal Embolden trial is on track to complete in 3–6 months, with strong regulatory alignment.
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Transcript: H. C. Wainwright Genetic Medicines Virtual Conference
Recent FDA discussions enable imminent dosing in the embolden study, with ICV administration shown to deliver superior brain drug levels. Focus is on durable, multi-domain efficacy and early-age enrollment, with regulatory and trial design advantages supporting broad market potential.
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
In May, FDA Commissioner Marty Makary named Vinay Prasad the next director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER). Within three months, Pr...
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...